|
Transplant Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care |
Apr 2023 |
Transplantation and Cellular Therapy |
Myelodysplastic Syndromes (MDS) |
|
Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care |
Jul 2023 |
Transplantation and Cellular Therapy |
Myelodysplastic Syndromes (MDS) |
|
Treatment Considerations of Myelodysplastic Syndromes/Neoplasms for Pathologists |
Dec 2023 |
Clinics in Laboratory Medicine |
Myelodysplastic Syndromes (MDS) |
|
Treatment of eculizumab refractory paroxysmal nocturnal hemoglobinuria: A systematic review about current treatment options and future direction |
Jun 2023 |
SAGE Open Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Treatment of lower-risk myelodysplastic syndromes |
Oct 2024 |
Haematologica |
Myelodysplastic Syndromes (MDS) |
|
Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities |
Apr 2024 |
Current Hematologic Malignancy Reports |
Myelodysplastic Syndromes (MDS) |
|
Treatment of newly diagnosed severe aplastic anemia in children: Evidence-based recommendations |
May 2024 |
Pediatric Blood & Cancer |
Aplastic Anemia |
|
Treatment of newly diagnosed severe aplastic anemia in children: Evidence-based recommendations |
Aug 2024 |
Pediatric Blood Cancer |
Aplastic Anemia, Pediatric |
|
Treatment of relapsed/refractory severe aplastic anemia in children: Evidence-based recommendations |
Aug 2024 |
Pediatric Blood Cancer |
Aplastic Anemia |
|
Treatment options for lower-risk myelodysplastic syndromes. Where are we now? |
Jan 2021 |
Therapeutic Advances in Hematology |
Myelodysplastic Syndromes (MDS) |
